Statement of Changes in Beneficial Ownership (4)
22 6월 2021 - 6:29AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Gaenzle Christopher L |
2. Issuer Name and Ticker or Trading Symbol
PRA Health Sciences, Inc.
[
PRAH
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) EVP, CAO & General Counsel |
(Last)
(First)
(Middle)
C/O PRA HEALTH SCIENCES, INC., 4130 PARKLAKE AVENUE, SUITE 400 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
6/17/2021 |
(Street)
RALEIGH, NC 27612
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 6/17/2021 | | M | | 4213 | A | $95.94 | 38713 | D | |
Common Stock | 6/17/2021 | | M | | 18958 | A | $101.42 | 57671 | D | |
Common Stock | 6/17/2021 | | M | | 4326 | A | $103.30 | 61997 | D | |
Common Stock | 6/17/2021 | | S(1) | | 1300 | D | $167.40 (2) | 60697 | D | |
Common Stock | 6/17/2021 | | S(1) | | 13391 | D | $168.06 (3) | 47306 | D | |
Common Stock | 6/17/2021 | | S(1) | | 12114 | D | $169.41 (4) | 35192 | D | |
Common Stock | 6/17/2021 | | S(1) | | 692 | D | $169.75 (5) | 34500 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Options (Right to Buy) | $95.94 | 6/17/2021 | | M | | | 4213 | (6) | 8/13/2029 | Common Stock | 4213 | $0 | 16666 | D | |
Stock Options (Right to Buy) | $101.42 | 6/17/2021 | | M | | | 18958 | (7) | 8/10/2028 | Common Stock | 18958 | $0 | 37500 | D | |
Stock Options (Right to Buy) | $103.30 | 6/17/2021 | | M | | | 4326 | (8) | 6/1/2030 | Common Stock | 4326 | $0 | 17114 | D | |
Explanation of Responses: |
(1) | The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. |
(2) | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $166.72 to $167.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2), (3), (4) and (5) to this Form 4. |
(3) | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $167.72 to $168.67, inclusive. |
(4) | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $168.73 to $169.70, inclusive. |
(5) | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $169.73 to $169.79, inclusive. |
(6) | The option vests in three equal annual installments of 8,334 beginning on August 13, 2020. |
(7) | The option vests in four equal annual installments of 18,750 beginning on August 10, 2019. |
(8) | The option vests in three equal annual installments of 8,556 beginning on June 1, 2021. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Gaenzle Christopher L C/O PRA HEALTH SCIENCES, INC. 4130 PARKLAKE AVENUE, SUITE 400 RALEIGH, NC 27612 |
|
| EVP, CAO & General Counsel |
|
Signatures
|
By: /s/ Christopher L. Gaenzle | | 6/21/2021 |
**Signature of Reporting Person | Date |
PRA Health Sciences (NASDAQ:PRAH)
과거 데이터 주식 차트
부터 8월(8) 2024 으로 9월(9) 2024
PRA Health Sciences (NASDAQ:PRAH)
과거 데이터 주식 차트
부터 9월(9) 2023 으로 9월(9) 2024
PRA Health Sciences Inc (나스닥)의 실시간 뉴스: 최근 기사 0
More Pra Health Sciences, Inc. News Articles